Literature DB >> 10513641

Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load.

J Szabó1, Z Prohászka, F D Tóth, A Gyuris, J Segesdi, D Bánhegyi, E Ujhelyi, J Minárovits, G Füst.   

Abstract

OBJECTIVE: We have previously demonstrated that complement-mediated antibody-dependent enhancement (C-ADE) of HIV-1 infection correlates with accelerated immunosuppression and disease progression in HIV-1-infected individuals. In the present work the relationship between C-ADE and plasma HIV-1 RNA concentrations was studied to determine the effect of C-ADE on viral replication.
METHODS: Three studies were performed: (a) C-ADE and HIV-1 RNA concentrations were determined in the serum and plasma aliquots taken at the same time from 98 HIV patients, mostly in the advanced stage of the disease; (b) the above two parameters as well as HIV enzyme-linked immunosorbent assay (ELISA)-reactive antibodies (Abbott HIV 1/2 test), and p24 antigen levels (Abbott antigen test; Abbott, Delkenheim, Germany) were determined in four seroconversion panels purchased from the Boston Biomedica firm; (c) changes of HIV-1 RNA concentration and C-ADE during a 17 month follow-up period were determined in 18 HIV-infected patients. C-ADE was measured by the method previously established in our laboratories. The results were expressed by an enhancement/neutralization index (E/NI). HIV-1 RNA levels were determined with the Amplicor monitor kit (Roche, Basel, Switzerland), and in some experiments with the nucleic acid sequence based amplification (Organon Teknika, Turnhout, Belgium) kits.
RESULTS: (a) We found a highly significant (P<0.0001) positive correlation between E/NI values reflecting the extent of HIV-1 infection enhancement and plasma HIV-1 RNA levels. Both E/NI and HIV-1 RNA levels negatively correlated to the CD4 cell counts. (b) C-ADE was first detected just before, or concomitantly with, seroconversion in 4/4 seroconversion panels. (c) Both E/NI values and HIV-1 RNA levels significantly (P<0.001) increased during a 17 month observation period in 18 HIV-infected patients.
CONCLUSION: We found strong association between the extent of the complement-mediated antibody-dependent enhancement of HIV-1 infection and the plasma viral load in HIV patients. On the basis of these findings, C-ADE correlates with HIV replication in vivo, and potentially contributes to the progression of HIV disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10513641     DOI: 10.1097/00002030-199910010-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

2.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).

Authors:  Robert McLinden; Robert Paris; Victoria Polonis; Nicole Close; Zhaohui Su; Cecilia Shikuma; David Margolis; Jerome Kim
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

4.  Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.

Authors:  Dimitri Lavillette; Yoann Morice; Georgios Germanidis; Peggy Donot; Alexandre Soulier; Emanuil Pagkalos; Georgios Sakellariou; Liliane Intrator; Birke Bartosch; Jean-Michel Pawlotsky; François-Loïc Cosset
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

6.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

7.  A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.

Authors:  Keith Meyer; Arup Banerjee; Sharon E Frey; Robert B Belshe; Ranjit Ray
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

8.  B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.

Authors:  S Moir; A Malaspina; Y Li; T W Chun; T Lowe; J Adelsberger; M Baseler; L A Ehler; S Liu; R T Davey; J A Mican; A S Fauci
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

9.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Authors:  Craig Miller; Mauren Emanuelli; Elizabeth Fink; Esther Musselman; Ryan Mackie; Ryan Troyer; John Elder; Sue VandeWoude
Journal:  NPJ Vaccines       Date:  2018-04-30       Impact factor: 7.344

Review 10.  Applications of the FIV Model to Study HIV Pathogenesis.

Authors:  Craig Miller; Zaid Abdo; Aaron Ericsson; John Elder; Sue VandeWoude
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.